

Global Human Plasma-based Hyperimmune Preparation Market Growth 2026-2032

<https://marketpublishers.com/r/G689B83D7960EN.html>

Date: April 2026

Pages: 121

Price: US\$ 3,660.00 (Single User License)

ID: G689B83D7960EN

Abstracts

The global Human Plasma-based Hyperimmune Preparation market size is predicted to grow from US\$ 2163 million in 2025 to US\$ 3308 million in 2032; it is expected to grow at a CAGR of 6.4% from 2026 to 2032.

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides 'passive' immunity to the patient against an agent. This is in contrast to vaccines that provide 'active' immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant 'passive' short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the

preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.

LP Information, Inc. (LPI) ' newest research report, the "Human Plasma-based Hyperimmune Preparation Industry Forecast" looks at past sales and reviews total world Human Plasma-based Hyperimmune Preparation sales in 2025, providing a comprehensive analysis by region and market sector of projected Human Plasma-based Hyperimmune Preparation sales for 2026 through 2032. With Human Plasma-based Hyperimmune Preparation sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Human Plasma-based Hyperimmune Preparation industry.

This Insight Report provides a comprehensive analysis of the global Human Plasma-based Hyperimmune Preparation landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Plasma-based Hyperimmune Preparation portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Human Plasma-based Hyperimmune Preparation market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Plasma-based Hyperimmune Preparation and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Plasma-based Hyperimmune Preparation.

This report presents a comprehensive overview, market shares, and growth opportunities of Human Plasma-based Hyperimmune Preparation market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Hepatitis B Immunoglobulins

Rabies Immunoglobulins

Tetanus Immunoglobulins

Rho(D) Immunoglobulins

Other

Segmentation by Application:

Government Institution

Private Sector

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

CSL Behring

Grifols

Biotest

Kedrion

CBPO

Emergent (Cangene)

Kamada

CNBG

Hualan Bio

Shanghai RAAS

Sichuan Yuanda Shuyang

ADMA Biologics

Key Questions Addressed in this Report

What is the 10-year outlook for the global Human Plasma-based Hyperimmune Preparation market?

What factors are driving Human Plasma-based Hyperimmune Preparation market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Human Plasma-based Hyperimmune Preparation market opportunities vary by end market size?

How does Human Plasma-based Hyperimmune Preparation break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Human Plasma-based Hyperimmune Preparation Annual Sales 2021-2032

2.1.2 World Current & Future Analysis for Human Plasma-based Hyperimmune Preparation by Geographic Region, 2021, 2025 & 2032

2.1.3 World Current & Future Analysis for Human Plasma-based Hyperimmune Preparation by Country/Region, 2021, 2025 & 2032

2.2 Human Plasma-based Hyperimmune Preparation Segment by Type

2.2.1 Hepatitis B Immunoglobulins

2.2.2 Rabies Immunoglobulins

2.2.3 Tetanus Immunoglobulins

2.2.4 Rho(D) Immunoglobulins

2.2.5 Other

2.2.6 Human Plasma-based Hyperimmune Preparation Sales by Type

2.2.6.1 Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Type (2021-2026)

2.2.6.2 Global Human Plasma-based Hyperimmune Preparation Revenue and Market Share by Type (2021-2026)

2.2.6.3 Global Human Plasma-based Hyperimmune Preparation Sale Price by Type (2021-2026)

2.3 Human Plasma-based Hyperimmune Preparation Segment by Application

2.3.1 Government Institution

2.3.2 Private Sector

2.3.3 Others

2.3.4 Human Plasma-based Hyperimmune Preparation Sales by Application

2.3.4.1 Global Human Plasma-based Hyperimmune Preparation Sale Market Share by Application (2021-2026)

2.3.4.2 Global Human Plasma-based Hyperimmune Preparation Revenue and Market Share by Application (2021-2026)

2.3.4.3 Global Human Plasma-based Hyperimmune Preparation Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Human Plasma-based Hyperimmune Preparation Breakdown Data by Company

3.1.1 Global Human Plasma-based Hyperimmune Preparation Annual Sales by Company (2021-2026)

3.1.2 Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Company (2021-2026)

3.2 Global Human Plasma-based Hyperimmune Preparation Annual Revenue by Company (2021-2026)

3.2.1 Global Human Plasma-based Hyperimmune Preparation Revenue by Company (2021-2026)

3.2.2 Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Company (2021-2026)

3.3 Global Human Plasma-based Hyperimmune Preparation Sale Price by Company

3.4 Key Manufacturers Human Plasma-based Hyperimmune Preparation Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Human Plasma-based Hyperimmune Preparation Product Location Distribution

3.4.2 Players Human Plasma-based Hyperimmune Preparation Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR HUMAN PLASMA-BASED HYPERIMMUNE PREPARATION BY GEOGRAPHIC REGION

4.1 World Historic Human Plasma-based Hyperimmune Preparation Market Size by Geographic Region (2021-2026)

- 4.1.1 Global Human Plasma-based Hyperimmune Preparation Annual Sales by Geographic Region (2021-2026)
- 4.1.2 Global Human Plasma-based Hyperimmune Preparation Annual Revenue by Geographic Region (2021-2026)
- 4.2 World Historic Human Plasma-based Hyperimmune Preparation Market Size by Country/Region (2021-2026)
 - 4.2.1 Global Human Plasma-based Hyperimmune Preparation Annual Sales by Country/Region (2021-2026)
 - 4.2.2 Global Human Plasma-based Hyperimmune Preparation Annual Revenue by Country/Region (2021-2026)
- 4.3 Americas Human Plasma-based Hyperimmune Preparation Sales Growth
- 4.4 APAC Human Plasma-based Hyperimmune Preparation Sales Growth
- 4.5 Europe Human Plasma-based Hyperimmune Preparation Sales Growth
- 4.6 Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales Growth

5 AMERICAS

- 5.1 Americas Human Plasma-based Hyperimmune Preparation Sales by Country
 - 5.1.1 Americas Human Plasma-based Hyperimmune Preparation Sales by Country (2021-2026)
 - 5.1.2 Americas Human Plasma-based Hyperimmune Preparation Revenue by Country (2021-2026)
- 5.2 Americas Human Plasma-based Hyperimmune Preparation Sales by Type (2021-2026)
- 5.3 Americas Human Plasma-based Hyperimmune Preparation Sales by Application (2021-2026)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Human Plasma-based Hyperimmune Preparation Sales by Region
 - 6.1.1 APAC Human Plasma-based Hyperimmune Preparation Sales by Region (2021-2026)
 - 6.1.2 APAC Human Plasma-based Hyperimmune Preparation Revenue by Region (2021-2026)

6.2 APAC Human Plasma-based Hyperimmune Preparation Sales by Type (2021-2026)

6.3 APAC Human Plasma-based Hyperimmune Preparation Sales by Application
(2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Human Plasma-based Hyperimmune Preparation by Country

7.1.1 Europe Human Plasma-based Hyperimmune Preparation Sales by Country
(2021-2026)

7.1.2 Europe Human Plasma-based Hyperimmune Preparation Revenue by Country
(2021-2026)

7.2 Europe Human Plasma-based Hyperimmune Preparation Sales by Type
(2021-2026)

7.3 Europe Human Plasma-based Hyperimmune Preparation Sales by Application
(2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Human Plasma-based Hyperimmune Preparation by Country

8.1.1 Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales by
Country (2021-2026)

8.1.2 Middle East & Africa Human Plasma-based Hyperimmune Preparation Revenue
by Country (2021-2026)

8.2 Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales by
Type (2021-2026)

8.3 Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales by
Application (2021-2026)

- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Human Plasma-based Hyperimmune Preparation
- 10.3 Manufacturing Process Analysis of Human Plasma-based Hyperimmune Preparation
- 10.4 Industry Chain Structure of Human Plasma-based Hyperimmune Preparation

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Human Plasma-based Hyperimmune Preparation Distributors
- 11.3 Human Plasma-based Hyperimmune Preparation Customer

12 WORLD FORECAST REVIEW FOR HUMAN PLASMA-BASED HYPERIMMUNE PREPARATION BY GEOGRAPHIC REGION

- 12.1 Global Human Plasma-based Hyperimmune Preparation Market Size Forecast by Region
 - 12.1.1 Global Human Plasma-based Hyperimmune Preparation Forecast by Region (2027-2032)
 - 12.1.2 Global Human Plasma-based Hyperimmune Preparation Annual Revenue Forecast by Region (2027-2032)
- 12.2 Americas Forecast by Country (2027-2032)

- 12.3 APAC Forecast by Region (2027-2032)
- 12.4 Europe Forecast by Country (2027-2032)
- 12.5 Middle East & Africa Forecast by Country (2027-2032)
- 12.6 Global Human Plasma-based Hyperimmune Preparation Forecast by Type (2027-2032)
- 12.7 Global Human Plasma-based Hyperimmune Preparation Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 CSL Behring

- 13.1.1 CSL Behring Company Information
- 13.1.2 CSL Behring Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
- 13.1.3 CSL Behring Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.1.4 CSL Behring Main Business Overview
- 13.1.5 CSL Behring Latest Developments

13.2 Grifols

- 13.2.1 Grifols Company Information
- 13.2.2 Grifols Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
- 13.2.3 Grifols Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.2.4 Grifols Main Business Overview
- 13.2.5 Grifols Latest Developments

13.3 Biotest

- 13.3.1 Biotest Company Information
- 13.3.2 Biotest Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
- 13.3.3 Biotest Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.3.4 Biotest Main Business Overview
- 13.3.5 Biotest Latest Developments

13.4 Kedrion

- 13.4.1 Kedrion Company Information
- 13.4.2 Kedrion Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
- 13.4.3 Kedrion Human Plasma-based Hyperimmune Preparation Sales, Revenue,

Price and Gross Margin (2021-2026)

13.4.4 Kedrion Main Business Overview

13.4.5 Kedrion Latest Developments

13.5 CBPO

13.5.1 CBPO Company Information

13.5.2 CBPO Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

13.5.3 CBPO Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 CBPO Main Business Overview

13.5.5 CBPO Latest Developments

13.6 Emergent (Cangene)

13.6.1 Emergent (Cangene) Company Information

13.6.2 Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

13.6.3 Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 Emergent (Cangene) Main Business Overview

13.6.5 Emergent (Cangene) Latest Developments

13.7 Kamada

13.7.1 Kamada Company Information

13.7.2 Kamada Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

13.7.3 Kamada Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 Kamada Main Business Overview

13.7.5 Kamada Latest Developments

13.8 CNBG

13.8.1 CNBG Company Information

13.8.2 CNBG Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

13.8.3 CNBG Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 CNBG Main Business Overview

13.8.5 CNBG Latest Developments

13.9 Hualan Bio

13.9.1 Hualan Bio Company Information

13.9.2 Hualan Bio Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

13.9.3 Hualan Bio Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 Hualan Bio Main Business Overview

13.9.5 Hualan Bio Latest Developments

13.10 Shanghai RAAS

13.10.1 Shanghai RAAS Company Information

13.10.2 Shanghai RAAS Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

13.10.3 Shanghai RAAS Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 Shanghai RAAS Main Business Overview

13.10.5 Shanghai RAAS Latest Developments

13.11 Sichuan Yuanda Shuyang

13.11.1 Sichuan Yuanda Shuyang Company Information

13.11.2 Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

13.11.3 Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Sichuan Yuanda Shuyang Main Business Overview

13.11.5 Sichuan Yuanda Shuyang Latest Developments

13.12 ADMA Biologics

13.12.1 ADMA Biologics Company Information

13.12.2 ADMA Biologics Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

13.12.3 ADMA Biologics Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2021-2026)

13.12.4 ADMA Biologics Main Business Overview

13.12.5 ADMA Biologics Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Human Plasma-based Hyperimmune Preparation Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Human Plasma-based Hyperimmune Preparation Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Hepatitis B Immunoglobulins

Table 4. Major Players of Rabies Immunoglobulins

Table 5. Major Players of Tetanus Immunoglobulins

Table 6. Major Players of Rho(D) Immunoglobulins

Table 7. Major Players of Other

Table 8. Global Human Plasma-based Hyperimmune Preparation Sales by Type (2021-2026) & (K Units)

Table 9. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Type (2021-2026)

Table 10. Global Human Plasma-based Hyperimmune Preparation Revenue by Type (2021-2026) & (\$ million)

Table 11. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Type (2021-2026)

Table 12. Global Human Plasma-based Hyperimmune Preparation Sale Price by Type (2021-2026) & (US\$/Unit)

Table 13. Global Human Plasma-based Hyperimmune Preparation Sale by Application (2021-2026) & (K Units)

Table 14. Global Human Plasma-based Hyperimmune Preparation Sale Market Share by Application (2021-2026)

Table 15. Global Human Plasma-based Hyperimmune Preparation Revenue by Application (2021-2026) & (\$ million)

Table 16. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Application (2021-2026)

Table 17. Global Human Plasma-based Hyperimmune Preparation Sale Price by Application (2021-2026) & (US\$/Unit)

Table 18. Global Human Plasma-based Hyperimmune Preparation Sales by Company (2021-2026) & (K Units)

Table 19. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Company (2021-2026)

Table 20. Global Human Plasma-based Hyperimmune Preparation Revenue by Company (2021-2026) & (\$ millions)

Table 21. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Company (2021-2026)

Table 22. Global Human Plasma-based Hyperimmune Preparation Sale Price by Company (2021-2026) & (US\$/Unit)

Table 23. Key Manufacturers Human Plasma-based Hyperimmune Preparation Producing Area Distribution and Sales Area

Table 24. Players Human Plasma-based Hyperimmune Preparation Products Offered

Table 25. Human Plasma-based Hyperimmune Preparation Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 26. New Products and Potential Entrants

Table 27. Market M&A Activity & Strategy

Table 28. Global Human Plasma-based Hyperimmune Preparation Sales by Geographic Region (2021-2026) & (K Units)

Table 29. Global Human Plasma-based Hyperimmune Preparation Sales Market Share Geographic Region (2021-2026)

Table 30. Global Human Plasma-based Hyperimmune Preparation Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 31. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Geographic Region (2021-2026)

Table 32. Global Human Plasma-based Hyperimmune Preparation Sales by Country/Region (2021-2026) & (K Units)

Table 33. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Country/Region (2021-2026)

Table 34. Global Human Plasma-based Hyperimmune Preparation Revenue by Country/Region (2021-2026) & (\$ millions)

Table 35. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Country/Region (2021-2026)

Table 36. Americas Human Plasma-based Hyperimmune Preparation Sales by Country (2021-2026) & (K Units)

Table 37. Americas Human Plasma-based Hyperimmune Preparation Sales Market Share by Country (2021-2026)

Table 38. Americas Human Plasma-based Hyperimmune Preparation Revenue by Country (2021-2026) & (\$ millions)

Table 39. Americas Human Plasma-based Hyperimmune Preparation Sales by Type (2021-2026) & (K Units)

Table 40. Americas Human Plasma-based Hyperimmune Preparation Sales by Application (2021-2026) & (K Units)

Table 41. APAC Human Plasma-based Hyperimmune Preparation Sales by Region (2021-2026) & (K Units)

Table 42. APAC Human Plasma-based Hyperimmune Preparation Sales Market Share by Region (2021-2026)

Table 43. APAC Human Plasma-based Hyperimmune Preparation Revenue by Region (2021-2026) & (\$ millions)

Table 44. APAC Human Plasma-based Hyperimmune Preparation Sales by Type (2021-2026) & (K Units)

Table 45. APAC Human Plasma-based Hyperimmune Preparation Sales by Application (2021-2026) & (K Units)

Table 46. Europe Human Plasma-based Hyperimmune Preparation Sales by Country (2021-2026) & (K Units)

Table 47. Europe Human Plasma-based Hyperimmune Preparation Revenue by Country (2021-2026) & (\$ millions)

Table 48. Europe Human Plasma-based Hyperimmune Preparation Sales by Type (2021-2026) & (K Units)

Table 49. Europe Human Plasma-based Hyperimmune Preparation Sales by Application (2021-2026) & (K Units)

Table 50. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales by Country (2021-2026) & (K Units)

Table 51. Middle East & Africa Human Plasma-based Hyperimmune Preparation Revenue Market Share by Country (2021-2026)

Table 52. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales by Type (2021-2026) & (K Units)

Table 53. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales by Application (2021-2026) & (K Units)

Table 54. Key Market Drivers & Growth Opportunities of Human Plasma-based Hyperimmune Preparation

Table 55. Key Market Challenges & Risks of Human Plasma-based Hyperimmune Preparation

Table 56. Key Industry Trends of Human Plasma-based Hyperimmune Preparation

Table 57. Human Plasma-based Hyperimmune Preparation Raw Material

Table 58. Key Suppliers of Raw Materials

Table 59. Human Plasma-based Hyperimmune Preparation Distributors List

Table 60. Human Plasma-based Hyperimmune Preparation Customer List

Table 61. Global Human Plasma-based Hyperimmune Preparation Sales Forecast by Region (2027-2032) & (K Units)

Table 62. Global Human Plasma-based Hyperimmune Preparation Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 63. Americas Human Plasma-based Hyperimmune Preparation Sales Forecast by Country (2027-2032) & (K Units)

Table 64. Americas Human Plasma-based Hyperimmune Preparation Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 65. APAC Human Plasma-based Hyperimmune Preparation Sales Forecast by Region (2027-2032) & (K Units)

Table 66. APAC Human Plasma-based Hyperimmune Preparation Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 67. Europe Human Plasma-based Hyperimmune Preparation Sales Forecast by Country (2027-2032) & (K Units)

Table 68. Europe Human Plasma-based Hyperimmune Preparation Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 69. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales Forecast by Country (2027-2032) & (K Units)

Table 70. Middle East & Africa Human Plasma-based Hyperimmune Preparation Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 71. Global Human Plasma-based Hyperimmune Preparation Sales Forecast by Type (2027-2032) & (K Units)

Table 72. Global Human Plasma-based Hyperimmune Preparation Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 73. Global Human Plasma-based Hyperimmune Preparation Sales Forecast by Application (2027-2032) & (K Units)

Table 74. Global Human Plasma-based Hyperimmune Preparation Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 75. CSL Behring Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors

Table 76. CSL Behring Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

Table 77. CSL Behring Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 78. CSL Behring Main Business

Table 79. CSL Behring Latest Developments

Table 80. Grifols Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors

Table 81. Grifols Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

Table 82. Grifols Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 83. Grifols Main Business

Table 84. Grifols Latest Developments

Table 85. Biotest Basic Information, Human Plasma-based Hyperimmune Preparation

Manufacturing Base, Sales Area and Its Competitors

Table 86. Biotest Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

Table 87. Biotest Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 88. Biotest Main Business

Table 89. Biotest Latest Developments

Table 90. Kedrion Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors

Table 91. Kedrion Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

Table 92. Kedrion Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 93. Kedrion Main Business

Table 94. Kedrion Latest Developments

Table 95. CBPO Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors

Table 96. CBPO Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

Table 97. CBPO Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 98. CBPO Main Business

Table 99. CBPO Latest Developments

Table 100. Emergent (Cangene) Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors

Table 101. Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

Table 102. Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 103. Emergent (Cangene) Main Business

Table 104. Emergent (Cangene) Latest Developments

Table 105. Kamada Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors

Table 106. Kamada Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

Table 107. Kamada Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 108. Kamada Main Business

Table 109. Kamada Latest Developments

Table 110. CNBG Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors

Table 111. CNBG Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

Table 112. CNBG Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 113. CNBG Main Business

Table 114. CNBG Latest Developments

Table 115. Hualan Bio Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors

Table 116. Hualan Bio Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

Table 117. Hualan Bio Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 118. Hualan Bio Main Business

Table 119. Hualan Bio Latest Developments

Table 120. Shanghai RAAS Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors

Table 121. Shanghai RAAS Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

Table 122. Shanghai RAAS Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 123. Shanghai RAAS Main Business

Table 124. Shanghai RAAS Latest Developments

Table 125. Sichuan Yuanda Shuyang Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors

Table 126. Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

Table 127. Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 128. Sichuan Yuanda Shuyang Main Business

Table 129. Sichuan Yuanda Shuyang Latest Developments

Table 130. ADMA Biologics Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors

Table 131. ADMA Biologics Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications

Table 132. ADMA Biologics Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 133. ADMA Biologics Main Business

Table 134. ADMA Biologics Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Human Plasma-based Hyperimmune Preparation
- Figure 2. Human Plasma-based Hyperimmune Preparation Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Human Plasma-based Hyperimmune Preparation Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Human Plasma-based Hyperimmune Preparation Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Human Plasma-based Hyperimmune Preparation Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Human Plasma-based Hyperimmune Preparation Sales Market Share by Country/Region (2025)
- Figure 10. Human Plasma-based Hyperimmune Preparation Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Hepatitis B Immunoglobulins
- Figure 12. Product Picture of Rabies Immunoglobulins
- Figure 13. Product Picture of Tetanus Immunoglobulins
- Figure 14. Product Picture of Rho(D) Immunoglobulins
- Figure 15. Product Picture of Other
- Figure 16. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Type in 2026
- Figure 17. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Type (2021-2026)
- Figure 18. Human Plasma-based Hyperimmune Preparation Consumed in Government Institution
- Figure 19. Global Human Plasma-based Hyperimmune Preparation Market: Government Institution (2021-2026) & (K Units)
- Figure 20. Human Plasma-based Hyperimmune Preparation Consumed in Private Sector
- Figure 21. Global Human Plasma-based Hyperimmune Preparation Market: Private Sector (2021-2026) & (K Units)
- Figure 22. Human Plasma-based Hyperimmune Preparation Consumed in Others
- Figure 23. Global Human Plasma-based Hyperimmune Preparation Market: Others (2021-2026) & (K Units)

Figure 24. Global Human Plasma-based Hyperimmune Preparation Sale Market Share by Application (2025)

Figure 25. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Application in 2026

Figure 26. Human Plasma-based Hyperimmune Preparation Sales by Company in 2026 (K Units)

Figure 27. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Company in 2026

Figure 28. Human Plasma-based Hyperimmune Preparation Revenue by Company in 2026 (\$ millions)

Figure 29. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Company in 2026

Figure 30. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Geographic Region (2021-2026)

Figure 31. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Geographic Region in 2026

Figure 32. Americas Human Plasma-based Hyperimmune Preparation Sales 2021-2026 (K Units)

Figure 33. Americas Human Plasma-based Hyperimmune Preparation Revenue 2021-2026 (\$ millions)

Figure 34. APAC Human Plasma-based Hyperimmune Preparation Sales 2021-2026 (K Units)

Figure 35. APAC Human Plasma-based Hyperimmune Preparation Revenue 2021-2026 (\$ millions)

Figure 36. Europe Human Plasma-based Hyperimmune Preparation Sales 2021-2026 (K Units)

Figure 37. Europe Human Plasma-based Hyperimmune Preparation Revenue 2021-2026 (\$ millions)

Figure 38. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales 2021-2026 (K Units)

Figure 39. Middle East & Africa Human Plasma-based Hyperimmune Preparation Revenue 2021-2026 (\$ millions)

Figure 40. Americas Human Plasma-based Hyperimmune Preparation Sales Market Share by Country in 2026

Figure 41. Americas Human Plasma-based Hyperimmune Preparation Revenue Market Share by Country (2021-2026)

Figure 42. Americas Human Plasma-based Hyperimmune Preparation Sales Market Share by Type (2021-2026)

Figure 43. Americas Human Plasma-based Hyperimmune Preparation Sales Market

Share by Application (2021-2026)

Figure 44. United States Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 45. Canada Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 46. Mexico Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 47. Brazil Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 48. APAC Human Plasma-based Hyperimmune Preparation Sales Market Share by Region in 2026

Figure 49. APAC Human Plasma-based Hyperimmune Preparation Revenue Market Share by Region (2021-2026)

Figure 50. APAC Human Plasma-based Hyperimmune Preparation Sales Market Share by Type (2021-2026)

Figure 51. APAC Human Plasma-based Hyperimmune Preparation Sales Market Share by Application (2021-2026)

Figure 52. China Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 53. Japan Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 54. South Korea Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 55. Southeast Asia Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 56. India Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 57. Australia Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 58. China Taiwan Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 59. Europe Human Plasma-based Hyperimmune Preparation Sales Market Share by Country in 2026

Figure 60. Europe Human Plasma-based Hyperimmune Preparation Revenue Market Share by Country (2021-2026)

Figure 61. Europe Human Plasma-based Hyperimmune Preparation Sales Market Share by Type (2021-2026)

Figure 62. Europe Human Plasma-based Hyperimmune Preparation Sales Market Share by Application (2021-2026)

Figure 63. Germany Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 64. France Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 65. UK Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 66. Italy Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 67. Russia Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 68. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales Market Share by Country (2021-2026)

Figure 69. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales Market Share by Type (2021-2026)

Figure 70. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales Market Share by Application (2021-2026)

Figure 71. Egypt Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 72. South Africa Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 73. Israel Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 74. Turkey Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 75. GCC Countries Human Plasma-based Hyperimmune Preparation Revenue Growth 2021-2026 (\$ millions)

Figure 76. Manufacturing Cost Structure Analysis of Human Plasma-based Hyperimmune Preparation in 2026

Figure 77. Manufacturing Process Analysis of Human Plasma-based Hyperimmune Preparation

Figure 78. Industry Chain Structure of Human Plasma-based Hyperimmune Preparation

Figure 79. Channels of Distribution

Figure 80. Global Human Plasma-based Hyperimmune Preparation Sales Market Forecast by Region (2027-2032)

Figure 81. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share Forecast by Region (2027-2032)

Figure 82. Global Human Plasma-based Hyperimmune Preparation Sales Market Share Forecast by Type (2027-2032)

Figure 83. Global Human Plasma-based Hyperimmune Preparation Revenue Market

Share Forecast by Type (2027-2032)

Figure 84. Global Human Plasma-based Hyperimmune Preparation Sales Market Share Forecast by Application (2027-2032)

Figure 85. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Human Plasma-based Hyperimmune Preparation Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G689B83D7960EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G689B83D7960EN.html>